Many pharma companies talk about the importance of ‘patient centric’ clinical trials and involving patients in trial design – but what does this really mean?
While the UK government has been applauded for its efforts in raising awareness about antimicrobial resistance, its efforts to convince pharma to invest in new antibiotics have so far been
The UK environment for drug discovery, the impact of artificial intelligence (AI) on medicines research and the role of complex cell models were all on the agenda for episode 12 of the
